| Schedule of Net Loss Per Share Basic and Diluted |
The
Net loss per share basic and diluted for the respective periods indicated is as follows:
Schedule
of Net Loss Per Share Basic and Diluted
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| | |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| Numerator | |
| | |
| | |
| | |
| |
| Net loss | |
$ | (4,439 | ) | |
$ | (11,005 | ) | |
$ | (31,347 | ) | |
$ | (21,617 | ) |
| Deemed dividend on Series A and Series A-1 Convertible Preferred Stock | |
| — | | |
| — | | |
| — | | |
| (7,496 | ) |
| Series B and Series B-1 Convertible Preferred Stock dividends earned | |
| (3,449 | ) | |
| — | | |
| (12,559 | ) | |
| — | |
| Net loss attributable to Lucid Diagnostics Inc. common stockholders | |
$ | (7,888 | ) | |
$ | (11,005 | ) | |
$ | (43,906 | ) | |
$ | (29,113 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Denominator | |
| | | |
| | | |
| | | |
| | |
| Weighted average common shares outstanding, basic and diluted | |
| 98,989,161 | | |
| 48,212,040 | | |
| 83,976,182 | | |
| 46,613,362 | |
| | |
| | | |
| | | |
| | | |
| | |
| Net loss per share (1) | |
| | | |
| | | |
| | | |
| | |
| Net loss per share - basic and diluted | |
$ | (0.08 | ) | |
$ | (0.23 | ) | |
$ | (0.52 | ) | |
$ | (0.62 | ) |
| (1) | | - Convertible Preferred
Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However,
the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no
impact on the Company’s net loss per share calculation for the periods indicated. |
|
| Schedule of Common Stock Equivalents Excluded from Computation of Diluted Earnings Per Share |
Schedule
of Common Stock Equivalents Excluded from Computation of Diluted Earnings Per Share
| | |
2025 | | |
2024 | |
| | |
June 30, | |
| | |
2025 | | |
2024 | |
| | |
| | |
| |
| Stock options | |
| 9,832,030 | | |
| 8,744,626 | |
| Unvested restricted stock awards | |
| 6,584,240 | | |
| 3,897,440 | |
| Preferred stock | |
| 49,607,115 | | |
| 51,682,378 | |
| Total | |
| 66,023,385 | | |
| 64,324,444 | |
|